



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

EP 03 110294

107528846

23 MAR 2005

REC'D 24 OCT 2003

WIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02021600.8

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

BEST AVAILABLE COPY



Anmeldung Nr:

Application no.: 02021600.8

Demande no:

Anmeldetag:

Date of filing: 27.09.02

Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Roche Vitamins AG

4070 Basel
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:

(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.

If no title is shown please refer to the description.

Si aucun titre n'est indiqué se référer à la description.)

Production of canthaxanthin by Phaffia

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)

Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C12P/

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

Roche Vitamins AG, CH-4070 Basle, Switzerland

Case 21414

Production of canthaxanthin by *Phaffia*

The present invention relates to production of xanthophyll carotenoids, especially canthaxanthin and echinenone by a microorganism belonging to the genus *Phaffia*.

More particularly, the present invention provides a process for producing xanthophyll carotenoids, especially canthaxanthin and echinenone by genetically modified recombi-
5 nant microorganism belonging to the genus *Phaffia*.

By using methods of the present invention, it becomes possible to produce the useful xanthophyll carotenoids other than astaxanthin such as canthaxanthin and echinenone as a major xanthophyll carotenoid in the recombinant microorganism belonging to *Phaffia*.

10 Any strain which is able to produce β -carotene can be a suitable host strain. When the selected host strain is a normal *Phaffia* strain which is capable of producing astaxanthin from β -carotene, production of mixture of astaxanthin and other xanthophyll carotenoids can be achieved after introduction and expression of a gene coding for β -carotene ketolase. On the other hand, when a strain which cannot produce astaxanthin and is
15 accumulating β -carotene is selected as the said host strain, it is expected to produce maximum level of xanthophyll carotenoids such as canthaxanthin and echinenone without accumulation of astaxanthin. Such a host strain which accumulates β -carotene can be obtained by mutagenesis of a strain of *Phaffia rhodozyma* accumulating astaxanthin. Alternatively, such a host strain accumulating β -carotene can also be obtained by
20 deactivating astaxanthin synthase which is an enzyme involved in the biosynthesis of astaxanthin from β -carotene and is disclosed in US 6,365,386. Disruption of the gene of astaxanthin synthase will be one of the most convenient ways to deactivate the enzyme.

Furthermore, such a host strain accumulating β -carotene can also be obtained from public type culture collections. For example, *P. rhodozyma* ATCC96815 accumulating β -carotene can be purchased from American Type Culture Collection (P.O.Box 1549, Manassas, VA 20108, USA). Isolating a new β -carotene accumulating strain of *P. rhodozyma*, which may be a derivative or a spontaneous mutant of astaxanthin producing strain, from nature will be another approach to prepare the host strain of the present invention.

An aspect of the present invention is a process for producing canthaxanthin and echinenone which comprises cultivating a recombinant *Phaffia* strain which is expressing the β -carotene ketolase.

Said β -carotene ketolase catalyzes conversion of methylene to keto groups at positions 4 and 4' on the β -ionone ring of β -carotene to produce the xanthophyll, canthaxanthin via echinenone. Genes encoding this enzyme have been isolated from several species, for example, *crtW* from marine bacteria (*Agrobacterium aurantiacum* and *Alcaligenes* sp.), *crtW* from *Paracoccus marcusii* (GenBank accession No. Y15112), *crtW* from *Paracoccus carotinifaciens* sp.nov., and *bkt* gene of *Haematococcus pluvialis* (GenBank accession No. D45881).

In the present invention, any gene encoding a protein having the β -carotene ketolase activity can be used.

Preferably, said β -carotene ketolase gene can be obtained from a microorganism which is selected from the group consisting of microorganisms of the genera *Agrobacterium*, *Alcaligenes*, *Paracoccus*, and *Haematococcus* having the β -carotene ketolase gene.

More preferably, said β -carotene ketolase gene can be obtained from a microorganism which is selected from the group consisting of *Agrobacterium aurantiacum* (GenBank accession No. D58420), *Alcaligenes* PC-1 (GenBank accession No. D58422), *Paracoccus marcusii* MH1 (GenBank accession No. Y15112), a gram-negative bacteria E-396 (FERM BP-4283) (the DNA sequence of the β -carotene ketolase gene originated from this microorganism can be seen in the description of JP-A Hei 10-155497), and *Haematococcus pluvialis* (GenBank accession No. D45881) which are having the β -carotene ketolase gene, the GenBank accession No. showing the DNA sequence of the β -carotene ketolase gene originated from the respective microorganism.

Still more preferably, said β -carotene ketolase gene can be obtained from *Alcaligenes* PC-1, or it can also be obtained as a DNA sequence which is substantially homologous thereto.

The expression "a DNA sequence which is substantially homologous" refers with respect to the DNA sequence encoding the β -carotene ketolase to a DNA sequence which encodes an amino acid sequence which shows more than 60%, preferably more than 70%, more preferably more than 80%, and most preferably more than 90% identical amino acids when compared to the amino acid sequence of crtW of *Alcaligenes* PC-1 and is the amino acid sequence of a polypeptide which shows the same type of enzymatic activity as the enzyme encoded by crtW of *Alcaligenes* PC-1.

- 10 By using the β -carotene ketolase gene, it is possible to render a microorganism belonging to genus *Phaffia* an ability to produce canthaxanthin and echinenone. The recombinant microorganism of *Phaffia* expressing a β -carotene ketolase gene can be prepared by the well-known recombinant technology.

- 15 The techniques used to isolate or clone a DNA encoding β -carotene ketolase of the present invention are known in the art and include isolation from genomic DNA. The cloning of the DNA sequence of the present invention from such genomic DNA can be effected by using the polymerase chain reaction (hereinafter referred to as PCR).

- 20 The isolated or cloned DNA encoding β -carotene ketolase can be preferably utilized after cloning on a suitable expression vector for expression of the enzyme in the host microorganism of *Phaffia*.

- "Expression vector" includes vectors which are capable of expressing DNA sequences contained therein where such sequences are operably linked to other sequences such as control sequences which are capable of effecting the expression of said DNA sequences in a microorganism belonging to genus *Phaffia*. The term "operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. The term "control sequence" is intended to include, at a minimum, components which are necessary for expression of the gene of interest, and may also include additional advantageous components. Generally the control sequences include promoters, terminators and, in some instances, enhancers, transactivators, or transcription factors. Constitutive promoters, such as the glyceraldehyde-3-dehydrogenase (GAP) gene-promoter derived from *P. rhodozyma* (WO 97/23,633), may be used to obtain constitutive expression. Inducible promoters can be also used in order to

achieve an exactly-controlled expression. One of the examples for the inducible promoters is the promoter of genes encoding heat shock proteins or amylase gene, and the like.

Methods which are well known to those skilled in the art may be used to construct said expression vectors.

- 5 It is implied, although not explicitly stated, that expression vectors must be replicable in the host organisms either as episomes or as an integral part of a chromosomal DNA. Generally, higher stability of the gene may be expected in the latter case. To integrate the expression vector into the chromosome of the host microorganism by a homologous recombination, a vector is prepared to contain at least a portion of the DNA fragment whose
10 sequence is homologous to the host genomic DNA. For this purpose, rDNA gene fragment can be effectively used in a microorganism belonging to *Phaffia*. The rDNA is a kind of satellite DNAs which exist in multicopies on the genome. By using the rDNA fragment as a targeting DNA on the expression vector, the objective DNA to be expressed on said vector can be integrated into the host genome, and also can exist as multicopies. This may
15 give the gene dosage effects which will contribute to the overexpression of the objective enzymes. In the Examples of the present invention, such rDNA fragment was conveniently used for this purpose. The invention is intended to include other forms of expression vectors which serve equivalent functions and which are, or subsequently become, known.

- An isolated DNA sequence encoding β -carotene ketolase may be manipulated in a variety
20 of ways to provide for expression of the polypeptide. Manipulation of the nucleotide sequence encoding said β -carotene ketolase prior to its insertion into an expression vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleotide sequences utilizing cloning methods are well known in the art.

- Recombinant DNA consisting of said gene of β -carotene ketolase which was cloned in the
25 expression vector will be introduced into a host microorganism. Methods for the introduction of foreign DNA into fungal cells including a microorganism belonging to *Phaffia* are well known in the art. These include, for example, transformation by the LiCl method, protoplast fusion, electroporation, particle-gun methods which comprises bombardment by particles coated with DNAs, and other methods known in the art. In the Examples of
30 the present invention, the particle-gun method was applied as a transformation method for *P. rhodozyma*. Procedures for the particle-gun method are well known to the person skilled in the art.

The recombinant organism thus obtained is capable of overexpressing the DNA sequence encoding β -carotene ketolase. Thus, the recombinant organism of the present invention is useful in the production process of xanthophyll carotenoids, especially canthaxanthin and echinenone.

- 5 A further aspect of the present invention is a biological process for producing canthaxanthin and echinenone which comprises cultivating the recombinant microorganism of *Phaffia* in the presence of substrate for producing carotenoids in an aqueous nutrient medium under aerobic conditions, and isolating the resulted carotenoids from the cells of said recombinant microorganism or from the cultured broth.
- 10 Carotenoids including the xanthophylls are normally produced by cultivating a strain of *Phaffia* in a medium which comprises suitable macro- and micronutrients for the cells, such as molasses, saccharose or glucose as a carbohydrate source for cell growth and also as a substrate for producing carotenoids, and nitrogen sources such as corn steep liquor, yeast extract, diammonium sulphate, ammonium phosphate, ammonium hydroxide or
- 15 urea, phosphorus sources such as ammonium phosphate and phosphoric acid and added micronutrients or mineral salts such as magnesium sulphate, zinc sulphate and biotin or desthiobiotin.

The preferable conditions for cultivation are a pH in the range of from 4 to 8 and a temperature in the range of from 15 to 26°C for 24 to 500 hours. More preferable conditions for

20 cultivation are a pH in the range of from 5 to 7 and a temperature in the range of from 18 to 22°C for 48 to 350 hours.

In the cultivation, aeration and agitation usually give favorable results for the production of carotenoids.

- Once carotenoids are produced by cultivating the recombinant strain of *Phaffia* using the
- 25 methods of the present invention, the carotenoids can be isolated either from the medium, in the case they are secreted into the medium, or from the cells of the microorganism and, if necessary, separated from other carotenoids that may be present in case one specific carotenoid is desired, by methods known in the art.

- Carotenoids produced in accordance with the present invention can be used in a process
- 30 for the preparation of food or feed. A man skilled in the art is familiar with such processes. Such compound food or feed can further comprise additives or components generally used for such purpose and known in the state of the art.

The following Examples further illustrate the present invention, but these are not thereby limiting the scope of the invention.

The following materials and methods were employed in the Example described below:

Strains

- 5 *P. rhodozyma* ATCC96594 (re-deposited under the accession No. ATCC 74438 on April 8, 1998 pursuant to the Budapest Treaty)
- P. rhodozyma* ATCC96815 (re-deposited under the accession No. ATCC 74486 on February 18, 1999 pursuant to the Budapest Treaty)
- E. coli* TOP10: F⁻, *mcrA*, delta(*mrr-hsdRMS-mcrBC*), phi80, delta(*lacZ* M15), delta(*lacX*74),
10 *recA1*, *deoR*, *araD139*, (*ara-leu*)7697, *galU*, *galK*, *rpsL* (Str^r), *endA1*, *nupG* (Invitrogen Corporation, Carlsbad, USA)

Vectors

pCR2.1-TOPO (Invitrogen Corporation, Carlsbad, USA)
pGEM-T (Promega Corporation, USA)

15 Methods

- Restriction enzymes and T4 DNA ligase were purchased from Takara Shuzo (Ohtsu, JP). Polymerase chain reaction (PCR) was performed with the thermal cycler from Perkin Elmer model 2400. Each PCR condition is described in examples. PCR primers were purchased from a commercial supplier. Fluorescent DNA primers for DNA sequencing were
20 purchased from Pharmacia. DNA sequencing was performed with the automated fluorescent DNA sequencer (ALFred, Pharmacia).

Authentic sample for β -carotene was purchased from WAKO (Osaka, Japan). Canthaxanthin and echinenone were obtained from Roche Vitamins AG (Basle, Switzerland).

Example 1: Preparation of components of the expression vector

- 25 The components of the expression vector, a G418 resistant gene, promoter and terminator region of glyceraldehyde-3-phosphate dehydrogenase gene (hereinafter referred to as GAP) of *P. rhodozyma*, and rDNA fragment of *P. rhodozyma* were prepared.
- A G418 resistant gene cassette was prepared as follows. A *Sac* I- linker was ligated into the unique *Hind* III site of the vector, pUC-G418 (US Patent No. 6,365,386 B1), which was
30 harboring the G418 resistant gene cassette, and resulted vector was named as pG418Sa512.
- A 1.7 kb *Kpn* I / *Sac* I fragment cut out from pG418Sa512 was used as a G418 resistant gene cassette.

Each of the promoter and the terminator of GAP gene and the rDNA fragment was obtained by PCR using the genomic DNA of *P. rhodozyma* ATCC 96594 as template. To obtain the genomic DNA, a QIAGEN Blood & Cell Culture DNA Midi Kit (QIAGEN, Germany) was used with the cells of *P. rhodozyma* ATCC 96594 obtained by overnight culture in YPD (Difco Laboratories) medium.

Using the prepared genomic DNA as a template, PCR was performed using an Advantage-HF PCR Kit (CLONTECH Laboratories, Inc., USA) and a thermal cycler (Perkin Elmer 2400, USA).

The synthetic primers used to amplify the promoter sequence of GAP were: GAP#1 (SEQ ID NO:1)(having a *Not* I site GCGGCCGC) and GAP#5 (SEQ ID NO:2)(having a *Sma* I site CCCGGGG).

The initial template denaturation step consisted of 5 min at 94°C. An amplification cycle of 30 seconds at 94°C, 30 seconds at 55°C, and 1 min at 72°C was repeated for 25 times. After additional 10 min reaction at 72°C, the reaction mixture was kept at 4°C. By this reaction, DNA fragment containing the GAP promoter (398 bp) was amplified. This amplified GAP promoter was ligated with a pCR2.1-TOPO vector and introduced into *E. coli* TOP 10 cells by using a TOPO TA Cloning kit (Invitrogen Corporation, USA). Several clones were selected for sequence analysis. The sequence of the cloned GAP promoter of each candidate clone was examined. One of the DNA clones that showed completely the same sequence as the GAP promoter of *P. rhodozyma* (GenBank accession No. Y08366) was named as pTOPO-pGAP2#1. A 398 bp *Not* I / *Sma* I fragment cut out from pTOPO-pGAP2#1 was used as the GAP promoter cassette.

The two synthetic primers used to amplify the terminator sequence of GAP were: GAP#33 (SEQ ID NO:3)(having a *Bam*H I-*Sal* I site GGATCCGTCGAC) and GAP#4 (SEQ ID NO:4)(having a *Kpn* I site GGTACC).

The PCR conditions were the same as those for the GAP promoter described above. By this reaction, DNA fragment containing the GAP terminator (302 bp) was amplified. This amplified GAP terminator was ligated with a pCR2.1-TOPO vector and introduced into *E. coli* TOP 10 cells by using the TOPO TA Cloning kit. Several clones were selected for sequence analysis. The sequence of the cloned GAP terminator of each candidate clone was examined. One of the DNA clones that showed completely the same sequence as the GAP terminator of *P. rhodozyma* (GenBank accession No. Y08366) was named as pTOPO-tGAP#1. A 302 bp *Bam*H I / *Kpn* I fragment which was cut out from pTOPO-tGAP#1 was used as the GAP terminator cassette.

The two synthetic primers used to amplify the rDNA fragment were: R#1 (SEQ ID NO:5) (having a *Sac* I site GAGCTC) and R#2 (SEQ ID NO:6)(having a *Not* I-*Sac* I site GCGGCCGCAGCTC).

The PCR conditions were the same as those for the GAP promoter described above. By this reaction, DNA fragment containing the rDNA (3126 bp) was amplified. This amplified rDNA was ligated with a pCR2.1-TOPO vector and introduced into *E. coli* TOP 10 cells by using the TOPO TA Cloning kit. Several clones were selected for sequence analysis. The sequence of the cloned the rDNA of each candidate clone was examined. One of the DNA clones that showed completely the same sequence as the rDNA of *P. rhodozyma* (GenBank accession No. D31656, AF139632) was named as pTOPO-rDNA#1. A 1960 bp *Sac* II / *Not* I fragment cut out from pTOPO-rDNA#1 was used as the rDNA cassette.

10 **Example 2: Construction of the expression vector carrying the β -carotene ketolase gene (*crtW*) and use for the production of canthaxanthin and echinenone**

PCR based gene synthesis was applied to obtain the nucleotide sequence of the artificial *crtW* gene encoding the β -carotene ketolase of *Alcaligenes* strain PC-1 by back translating the amino acid sequence (GenBank accession No. D58422). The detailed methods are described in the Example in US 6,124,113. In this case, each of two terminal primers are designed to introduce the restriction site of *Sma* I and *Bam* H I to the 5'-end and 3'-end of the *crtW* gene, respectively.

The expression vector carrying the *crtW* gene was constructed by ligating the rDNA cassette and the GAP promoter cassette (obtained in Example 1), the *crtW* gene constructed as described above, and the GAP terminator cassette and the G418 resistant gene cassette (obtained in Example 1) to be aligned in this order using a pGEM-T as a backbone.

The resulting expression vector was introduced into *P. rhodozyma* ATCC 96815 by using the particle-gun methods as described in EP 1,158 051.

25 The *crtW*-recombinant strains of *P. rhodozyma* ATCC 96815 thus obtained are cultivated in 50 ml production medium in 500 ml Erlenmeyer flask with shaking at 20°C for 7 days after inoculation of seed culture prepared in 7 ml seed medium in test tube (21 mm in diameter) with shaking at 20°C for 3 days. Appropriate volume of the culture broth was withdrawn and used for analysis of the cell growth and the productivity of carotenoids.

30 Medium composition was as follows:

Seed medium: Glucose 30.0 g/l, NH_4Cl 4.83 g/l, KH_2PO_4 1.0 g/l, $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ 0.88 g/l, NaCl 0.06 g/l, $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ 0.2 g/l, KH phtalate 20.0 g/l, $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ 28 mg/l, Trace element solution 0.3 ml, Vitamin stock solution 1.5 ml, (pH was adjusted at 5.4–5.6)

Trace element solution: 4N H₂SO₄ 100 ml/l, citric acid-H₂O 50.0 g/l, ZnSO₄-7H₂O 16.7 g/l, CuSO₄-5H₂O 2.5 g/l, MnSO₄-4,5H₂O 2.0 g/l, H₃BO₃ 2.0 g/l, Na₂MoO₄ 2.0 g/l, KI 0.5 g/l

Vitamin stock solution for seed medium: 4N- H₂SO₄ 17.5 ml/l, *myo*-Inositol 40.0 g/l,

- 5 Nicotinic acid 2.0 g/l, Ca-D-pantothenate 2.0 g/l, Vitamin B₁ (thiamin HCl) 2.0 g/l, *p*-Aminobenzoic acid 1.2 g/l, Vitamin B₆ (pyridoxine HCl) 0.2 g/l, Biotin stock solution 8.0 ml

Biotin stock solution was prepared by the addition of 4N- H₂SO₄ to 50 ml of ethanol to a total of 100 ml. Then, 400 mg of D-biotin was added.

- 10 Production medium: Glucose 22.0 g/l, KH₂PO₄ 14.25 g/l, MgSO₄-7H₂O 2.1 g/l, CaCl₂-2H₂O 0.865 g/l, (NH₄)₂SO₄ 3.7 g/l, FeSO₄-7H₂O 0.28 g/l, Trace element solution 4.2 ml, Vitamin stock solution 9.35 ml, (pH was adjusted at 5.5)

Vitamin stock solution for production medium: 4N H₂SO₄ 17.5 ml/l, Nicotinic acid 2.0 g/l, Ca-D-pantothenate 3.0 g/l, Vitamin B₁ (thiamin HCl) 2.0 g/l, *p*-Aminobenzoic acid 1.2 g/l, Vitamin B₆ (pyridoxine HCl) 0.2 g/l, Biotin stock solution 30.0 ml

- 15 A portion of the seed culture broth (2.5 ml) was transferred to 47.5 ml of the production medium in 500 ml Erlenmeyer flask. Then the cultivation was started at 20°C with rotary shaking at 200 rpm. At the second day of the fermentation, 5 ml of 50 % glucose solution was added to the medium and the fermentation continued. At the fourth day of the fermentation, 2 ml of cultured broth were withdrawn and 5 ml of 50 % glucose solution
- 20 added again to the medium, and cultivation was continued for additional 3 days. At the seventh day, an aliquot of the culture was withdrawn and used for analysis of the carotenoids production and the cell growth.

For analysis of the cell growth, optical density at 660 nm was measured by using UV-1200 photometer (Shimadzu Corp., Kyoto, Japan).

- 25 For analysis of the content of β-carotene, canthaxanthin and echinenone, the withdrawn broth was mixed with a solvent mixture (ethyl alcohol, hexane and ethyl acetate) and carotenoids were extracted from the broth and the cells of *P. rhodozyma* by vigorous shaking with glass beads. After extraction, disrupted cells and glass beads were removed by centrifugation and the resultant supernatant was analyzed by HPLC for the carotenoids content.
- 30 The HPLC conditions used were as follows: HPLC column: Chrompack Lichrosorb si-60 (4.6 mm, 250 mm); Temperature: room temperature; Eluent: acetone / hexane (18/82) add 1 ml / l of water to eluent; Injection volume: 10 µl; Flow rate: 2.0 ml / min; Detection: UV at 450 nm

- 10 -

Claims

1. A process for producing canthaxanthin and echinenone which comprises cultivating a recombinant microorganism which is expressing a β -carotene ketolase gene and belonging to the genus *Xanthophyllomyces* (*Phaffia*) in an aqueous nutrient medium under aerobic conditions, and isolating the resulted carotenoids from the cells of said recombinant microorganism or from the cultured broth.
2. The process according to claim 1, wherein the recombinant microorganism is derived from *Xanthophyllomyces dendrorhous* (*Phaffia rhodozyma*) ATCC96815, or a mutant thereof.
3. The process according to claim 1, wherein the β -carotene ketolase gene is originated from a microorganism which is selected from the group consisting of microorganisms of the genera *Agrobacterium*, *Alcaligenes*, *Paracoccus* and *Haematococcus* having the β -carotene ketolase gene.
4. The process according to claim 1, wherein the β -carotene ketolase gene is originated from a microorganism which is selected from the group consisting of *Agrobacterium aurantiacum*, *Alcaligenes* PC-1, *Paracoccus marcusii* MH1, a gram-negative bacteria E-396 (FERM BP-4283), and *Haematococcus pluvialis*, having the β -carotene ketolase gene.
5. The process according to claim 1, wherein the β -carotene ketolase gene is originated from *Alcaligenes* PC-1 or the DNA sequence of the β -carotene ketolase gene is substantially homologous thereto.
6. The process according to claim 1, wherein the β -carotene ketolase gene is expressed in the recombinant microorganism using the control sequences.
7. The process according to claim 1, wherein the cultivation is carried out at a pH in the range of from 4 to 8 and at a temperature in the range of from 15 to 26°C for 24 to 500 hours.
8. The process according to claim 7, wherein the cultivation is carried out at pH in the range of from 5 to 7 and at a temperature in the range of from 18 to 22°C for 48 to 350 hours.

- 11 -

SEQUENCE LISTING

<110> Roche Vitamins AG

<120> Production of canthaxanthin by Phaffia

<130> NDR5224

5 <160> 6

<170> PatentIn version 3.1

<210> 1

10 <211> 28

<212> DNA

<213> Artificial

15 <400> 1

gcggccgctg gtgggtgcat gtatgtac

28

<210> 2

20 <211> 26

<212> DNA

<213> Artificial

25 <400> 2

cccgggggatg gtaagagtgt tagaga

26

<210> 3

30 <211> 33

<212> DNA

<213> Artificial

35 <400> 3

ggatccgctcg actaaacggt tctctccaaa ccc

33

<210> 4

40 <211> 28

<212> DNA

<213> Artificial

- 12 -

<400> 4

ggtaccttga tcagataaaag atagagat

28

<210> 5

5 <211> 20

<212> DNA

<213> Artificial

10 <400> 5

gagctctcga gtggacggtg

20

<210> 6

15 <211> 28

<212> DNA

<213> Artificial

20 <400> 6

ggggcgcga gctcatcccg cttcactc

28

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.